Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

CHAPTER 1 INTRODUCTION

1.1 Report description

1.2 Key benefits

1.3 Key market segments

1.4 Research methodology

1.4.1 Secondary research

1.4.2 Primary research

1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope

3.2 Biomarker diagnosis vs. conventional diagnosis

3.3 Key findings

3.3.1 Drivers

3.3.1.1 Rise in incidence and prevalence of various cancer types

3.3.1.2 Growth in importance of biological and targeted drug therapies

3.3.1.3 Expiration of key patents and biosimilars impact

3.3.1.4 Increase in acquisitions and collaborations

3.3.1.5 Technological advancements

3.3.1.6 Accuracy and reliability

3.3.1.7 Rise in investment from government, public, and private sectors

3.3.1.8 Increase in clinical trials

3.3.1.9 Growth in popularity of personalized medicine and companion diagnostics

3.3.2 Restraints

3.3.2.1 High cost of drug development and threat of failure

3.3.2.2 Unregulated government regulation and reimbursement policies

3.3.2.3 Adverse effects of cancer drug therapy

3.3.3 Opportunities

3.3.3.1 Advancement of cancer drugs research

3.3.3.2 Increased focus towards advanced treatment protocols

3.3.3.3 Significant unmet need in cancer diagnosis

3.3.3.4 Increased awareness to reduce healthcare costs

3.3.3.5 Opportunities in emerging economies

3.3.4 Top investment pockets

3.3.5 Top winning strategies

3.4 Porters five forces analysis

3.4.1 High bargaining power of suppliers

3.4.2 Low bargaining power of buyers

3.4.3 High threat from substitutes

3.4.4 Low threat of new entrants

3.4.5 High intensity of competitive rivalry

3.5 Top player positioning, 2015

3.6 Patent analysis

3.6.1 U.S. patent analysis by market participant

3.6.2 Europe patent analysis by market participant

3.6.3 China patent analysis by market participant

3.6.4 Canada patent analysis by market participant

3.6.5 Japan patent analysis by market participant

3.6.6 Other countries patent analysis by market participant

3.7 Clinical trials

CHAPTER 4 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.1 Omic technologies

4.1.1 Key market trends

4.1.2 Key growth factors and opportunities

4.1.3 Market size and forecast

4.1.4 Genomics

4.1.4.1 Market size and forecast

4.1.4.2 Next-generation sequencing (NGS)

4.1.4.3 Microarray

4.1.4.4 Polymerase chain reaction (PCR)

4.1.5 Proteomics

4.1.5.1 Market size and forecast

4.1.5.2 Mass spectrometry

4.1.5.3D gel electrophoresis

4.1.5.4 Protein microarray technology

4.1.5.5 Antibody array technology

4.1.5.6 Peptide array technology

4.1.6 Other omic technologies

4.1.6.1 Market size and forecast

4.1.6.2 Metabolomics

4.1.6.3 Glycomics

4.2 Imaging technologies

4.2.1 Key market trends

4.2.2 Key growth factors and opportunities

4.2.3 Market size and forecast

4.2.4 Magnetic resonance imaging

4.2.5 Positron emission tomography

4.2.6 Computed tomography

4.2.7 Mammography

4.2.8 Ultrasound

4.3 Immunoassays

4.3.1 Key market trends

4.3.2 Key growth factors and opportunities

4.3.3 Market size and forecast

4.3.4 Immunohistochemistry tests

4.3.5 Enzyme-linked immunosorbent assay

4.3.6 Flow cytometry

4.4 Cytogenetics-based tests

4.4.1 Key market trends

4.4.2 Key growth factors and opportunities

4.4.3 Market size and forecast

4.4.4 In situ hybridization

4.4.5 Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])

CHAPTER 5 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)

5.1 Overview

5.1.1 Market size and forecast

5.2 Genetic biomarkers

5.2.1 Market size and forecast

5.3 Protein biomarkers

5.3.1 Market size and forecast

5.4 Glyco-biomarkers

5.4.1 Market size and forecast

CHAPTER 6 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 Lung cancer

6.2.1 Market size and forecast

6.3 Breast cancer

6.3.1 Market size and forecast

6.4 Colorectal cancer

6.4.1 Market size and forecast

6.5 Prostate cancer

6.5.1 Market size and forecast

6.1 Stomach cancer

6.1.1 Market size and forecast

6.2 Others

6.2.1 Market size and forecast

CHAPTER 7 CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022

7.1 Overview

7.1.1 Market size and forecast

7.2 Diagnostics

7.2.1 Market size and forecast

7.3 Drug discovery and development

7.3.1 Market size and forecast

7.4 Prognostics

7.4.1 Market size and forecast

7.5 Risk assessment

7.5.1 Market size and forecast

7.6 Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)

7.6.1 Market size and forecast

CHAPTER 8 CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key market trends

8.2.2 Growth factors and opportunities

8.2.3 Market size and forecast

8.2.3.1 U.S.: market size and forecast

8.2.3.2 Canada: market size and forecast

8.2.3.3 Mexico: market size and forecast

8.3 Europe

8.3.1 Key market trends

8.3.2 Growth factors and opportunities

8.3.3 Market size and forecast

8.3.3.1 Germany: market size and forecast

8.3.3.2 UK: market size and forecast

8.3.3.3 France: market size and forecast

8.3.3.4 Italy: market size and forecast

8.3.3.5 Russia: market size and forecast

8.3.3.6 Rest of Europe: market size and forecast

8.4 Asia-Pacific

8.4.1 Key market trends

8.4.2 Key growth factors and opportunities

8.4.3 Market size and forecast

8.4.3.1 Japan: market size and forecast

8.4.3.2 China: market size and forecast

8.4.3.3 India: market size and forecast

8.4.3.4 Australia: market size and forecast

8.4.3.5 Rest of Asia-Pacific: market size and forecast

8.5 LAMEA (Latin America, Middle East, and Africa)

8.5.1 Key market trends

8.5.2 Key growth factors and opportunities

8.5.2.1 Brazil: market size and forecast

8.5.2.2 Saudi Arabia: market size and forecast

8.5.2.3 UAE: market size and forecast

8.5.2.4 Rest of LAMEA: market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 F. Hoffmann-La Roche Ltd.

9.1.1 Company overview

9.1.2 Business performance

9.1.3 Key strategies and developments

9.2 Abbott Laboratories

9.2.1 Company overview

9.2.2 Company Snapshot

9.2.3 Operating business segments

9.2.4 Business performance

9.2.5 Key strategies & developments

9.3 GlaxoSmithKline plc

9.3.1 Company overview

9.3.2 Operating business segments

9.3.3 Business performance

9.3.4 Key strategies and developments

9.4 Novartis AG

9.4.1 Company overview

9.4.2 Operating business segments

9.4.3 Business performance

9.4.4 Key strategies and developments

9.5 Merck & Co., Inc.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Business performance

9.5.5 Key strategies and developments

9.6 Bristol-Myers Squibb

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Business performance

9.6.4 Key strategies and developments

9.7 Eli Lilly and Company

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Business performance

9.7.5 Key strategies and developments

9.8 Pfizer, Inc.

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Business performance

9.8.5 Key strategies and developments

9.9 Qiagen N.V.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Key strategy move and development

9.10 Genomic Health, Inc.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Business performance

9.10.4 Key strategies and developments

List of Figures

FIG. 1 CANCER BIOMARKERS MARKET: SEGMENTATION

FIG. 2 TOP IMPACTING FACTORS: CANCER BIOMARKERS MARKET, 2015-2022

FIG. 3 PERCENTAGE (%) OF NEW CANCERS CASES DIAGNOSED IN 2012

FIG. 4 TOP INVESTMENT POCKETS: CANCER BIOMARKERS, 2015-2022

FIG. 5 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION

FIG. 6 TOP WINNING STRATEGIES: NATURE & TYPE

FIG. 7 TYPES OF STRATEGIES DISTRIBUTION

FIG. 8 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES

FIG. 9 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES

FIG. 10 PORTERS FIVE FORCES ANALYSIS

FIG. 11 TOP PLAYER POSITIONING, 2015

FIG. 12 PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2016

FIG. 13 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

FIG. 14 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

FIG. 15 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

FIG. 16 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

FIG. 17 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

FIG. 18 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

FIG. 19 U.S.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 20 CANADA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 21 MEXICO: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 22 GERMANY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 23 U.K.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 24 FRANCE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 25 ITALY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 26 RUSSIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 27 REST OF EUROPE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 28 JAPAN: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 29 CHINA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 30 INDIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 31 AUSTRALIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 32 REST OF ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 33 BRAZIL: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 34 SAUDI ARABIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 35 UAE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 36 REST OF LAMEA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)

FIG. 37 ROCHE: NET SALES, 2013-2015 ($MILLION)

FIG. 38 ROCHE: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)

FIG. 39 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 40 ROCHE: STRATEGY SHARE, 2014-2016 (%)

FIG. 41 ABBOTT: NET SALES, 2013-2015 ($MILLION)

FIG. 42 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)

FIG. 43 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)

FIG. 44 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 45 ABBOTT: STRATEGY SHARE, 2014-2016 (%)

FIG. 46 GSK: NET SALES, 2013-2015 ($MILLION)

FIG. 47 GSK: REVENUE, BY SEGMENT, 2015 (%)

FIG. 48 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 49 GSK: STRATEGY SHARE, 2014-2016 (%)

FIG. 50 NOVARTIS: REVENUE, 2013-2015 ($MILLION)

FIG. 51 NOVARTIS: REVENUE, BY BUSINESS SEGMENT, 2015 (%)

FIG. 52 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 53 NOVARTIS: STRATEGY SHARE, 2014-2016 (%)

FIG. 54 MERCK: NET SALES, 2013-2015 ($MILLION)

FIG. 55 MERCK: REVENUE, BY BUSINESS SEGMENT, 2015 (%)

FIG. 56 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 57 MERCK: STRATEGY SHARE, 2014-2016 (%)

FIG. 58 BRISTOL-MYERS SQUIBB: NET SALES, 2013-2015 ($MILLION)

FIG. 59 BRISTOL-MYERS SQUIBB, REVENUE, BY GEOGRAPHY, 2015(%)

FIG. 60 BRISTOL-MYERS SQUIBB: STRATEGY SHARE, 2014-2016 (%)

FIG. 61 ELI LILLY: NET SALES, 2013-2015, ($MILLION)

FIG. 62 ELI LILLY: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)

FIG. 63 ELI LILLY: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 64 ELI LILLY: STRATEGY SHARE, 2014-2016 (%)

FIG. 65 PFIZER, INC.: NET SALES, 2013-2015, ($MILLION)

FIG. 66 PFIZER, INC.: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)

FIG. 67 PFIZER, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 68 PFIZER, INC.: STRATEGY SHARE, 2014-2016 (%)

FIG. 69 QIAGEN: NET SALES, 2013-2015, ($MILLION)

FIG. 70 QIAGEN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)

FIG. 71 QIAGEN: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 72 QIAGEN: STRATEGY SHARE, 2014-2016 (%)

FIG. 73 GENOMIC HEALTH: NET SALES, 2013-2015 ($MILLION)

FIG. 74 GENOMIC HEALTH: REVENUE, BY GEOGRAPHY, 2015 (%)

FIG. 75 GENOMIC HEALTH: STRATEGY SHARE, 2014-2016 (%)

List of Tables

TABLE 1 CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES

TABLE 2 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES (2012)

TABLE 3 REVENUE GENERATION OF BIOLOGICAL AND TARGETED DRUGS IN 2013 ($MILLION)

TABLE 4 KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES

TABLE 5 COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS

TABLE 6 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE, CANADA, CHINA, JAPAN, AND OTHERS, 2013 THROUGH 2016

TABLE 7 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

TABLE 8 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

TABLE 9 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016

TABLE 10 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016

TABLE 11 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

TABLE 12 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016

TABLE 13 CLINICAL TRIALS: CANCER BIOMARKERS

TABLE 14 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)

TABLE 15 WORLD OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 16 WORLD OMICS TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 17 GLOBAL GENOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 1 GLOBAL PROTEOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 2 GLOBAL OTHER OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 3 GLOBAL IMAGING TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 4 GLOBAL IMAGING TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 5 GLOBAL IMMUNOASSAYS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 6 GLOBAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 7 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 8 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 9 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 10 GLOBAL GENETIC BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 11 GLOBAL PROTEIN BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 12 GLOBAL GLYCO-BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 13 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)

TABLE 14 GLOBAL CANCER BIOMARKERS FOR LUNG CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 15 GLOBAL CANCER BIOMARKERS FOR BREAST CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 16 GLOBAL CANCER BIOMARKERS FOR COLORECTAL CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 17 GLOBAL CANCER BIOMARKERS FOR PROSTATE CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 18 GLOBAL CANCER BIOMARKERS FOR STOMACH CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 19 GLOBAL CANCER BIOMARKERS FOR OTHER CANCERS, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 20 CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 21 DIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 22 DRUG DISCOVERY AND DEVELOPMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 23 PROGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 24 RISK ASSESSMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 25 OTHERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)

TABLE 26 CANCER BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2020 ($MILLION)

TABLE 27 NORTH AMERICA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)

TABLE 28 NORTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 29 NORTH AMERICA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)

TABLE 30 NORTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)

TABLE 31 NORTH AMERICAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 32 EUROPEAN CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)

TABLE 33 EUROPEAN CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 34 EUROPEAN CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)

TABLE 35 EUROPEAN CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)

TABLE 36 EUROPEAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 37 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)

TABLE 38 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 39 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)

TABLE 40 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)

TABLE 41 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 42 LAMEA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)

TABLE 43 LAMEA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)

TABLE 44 LAMEA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)

TABLE 45 LAMEA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)

TABLE 46 LAMEA CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)

TABLE 47 ROCHE: COMPANY SNAPSHOT

TABLE 48 ABBOTT: COMPANY SNAPSHOT

TABLE 49 ABBOTT: OPERATING SEGMENTS

TABLE 50 GSK: COMPANY SNAPSHOT

TABLE 51 GSK: OPERATING SEGMENTS

TABLE 52 NOVARTIS: COMPANY SNAPSHOT

TABLE 53 NOVARTIS: OPERATING SEGMENTS

TABLE 54 MERCK: COMPANY SNAPSHOT

TABLE 55 MERCK: PRODUCT CATEGORIES

TABLE 56 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 58 ELI LILLY: OPERATING SEGMENTS

TABLE 59 PFIZER, INC.: COMPANY SNAPSHOT

TABLE 60 PFIZER, INC.: OPERATING SEGMENTS

TABLE 61 QIAGEN: COMPANY SNAPSHOT

TABLE 62 GENOMIC HEALTH: COMPANY SNAPSHOT